Application of carotene and rosmarinic acid-4-O-β-D-glucose in the preparation of drugs for treating thrombocytopenia
Through the composition of carotene and rosmarinic acid-4-O-β-D-glucose, the differentiation and maturation of megakaryocytes has been promoted, and the problems of short-acting and side effects of existing drugs for treating thrombocytopenia have been solved, and the number of platelets has been significantly improved. , provides a safe and effective treatment plan.
Patent Information
- Application Number
- CN202311248200.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-26
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-09-26
AI Technical Summary
The existing drugs for treating thrombocytopenia have short-acting effects, large side effects, many adverse reactions, and lack of drugs that effectively promote the differentiation and maturation of megakaryocytes, resulting in insufficient platelet production and affecting the health of patients and the effect of chemotherapy.
Pharmaceutical dosage forms made of monomeric compositions of carotene and rosemary acid-4-O-β-D-glucose and conventional pharmaceutical excipients, including tablets, capsules and injections, by promoting the differentiation and maturation of megakaryocytes, and producing platelets. .
It significantly improved the differentiation and maturation and polyploidization of megakaryocytes, increased the number of platelets, and provided a new long-term treatment plan for thrombocytopenia, reducing the occurrence of adverse reactions.
Smart Images

Figure CN117323341B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of thrombocytopenia, and more specifically, to the application of carotene and rosmarinic acid-4-O-β-D-glucose in the preparation of a medicament for treating thrombocytopenia. Background Art
[0002] Thrombocytopenia is common in refractory diseases such as acute and chronic immune thrombocytopenia (ITP), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and systemic lupus erythematosus (SLE), which are extremely harmful to people's health. In addition, clinically, radiotherapy and chemotherapy for malignant tumors cause serious damage to the patient's hematopoietic system, especially the megakaryocyte system, inhibiting its differentiation and maturation, resulting in long-term low platelet count and hemostatic dysfunction, causing complications such as bleeding, and affecting the progress of radiotherapy and chemotherapy. Bone marrow megakaryocytes are the precursor cells of platelets, and their proliferation and differentiation (maturation) status directly affects the number of platelets in peripheral blood. Megakaryocyte differentiation and maturation disorders are the key links in the onset and treatment of thrombocytopenia.
[0003] First-line treatment for immune thrombocytopenia includes glucocorticoids and high-dose immunoglobulin. Although the patient's platelet count can be increased in a short period of time, the commonly used glucocorticoids prednisone and dexamethasone can only achieve about 15% sustained relief. Long-term use will cause adverse reactions such as osteoporosis, femoral head necrosis, hypertension, and diabetes. Intravenous immunoglobulin has a fast response but is short-lived. Platelet-promoting drugs targeting megakaryocyte differentiation and maturation are the first choice for second-line treatment of ITP. Recommendations include recombinant human thrombopoietin (rhTPO), romiplostim (TPO mimetic) and eltrombopag (TPO receptor agonist). These drugs have a fast onset and are also commonly used clinical drugs for thrombocytopenia caused by tumor radiotherapy and chemotherapy. However, the efficacy is generally not maintained after discontinuation of the drug. Taking TPO or TPO mimetic peptides and analogs for patients at a sufficient time and in sufficient amounts can increase the number of platelets, but they have a particularly strong effect on the final generation process of releasing platelets, which may induce platelet aggregation and adhesion, affecting normal coagulation and hemostasis functions. Eltrombopag is a TPO receptor agonist that can induce megakaryocyte proliferation and differentiation to stimulate platelet production. However, it has adverse reactions such as upper respiratory tract infection, diarrhea, nasopharyngitis and joint pain, and may also cause liver toxicity. It is also expensive and difficult to use in clinical routine. Second-line treatments include anti-CD20 monoclonal antibodies and splenectomy. The side effects of the former include thrombosis, arrhythmia and infection risks; more than 1 / 3 of patients have no response or relapse after surgery after splenectomy, and the risk of thrombosis increases. Other second-line treatment drugs, such as cyclosporine, danazol, and vinca alkaloids, lack data support from evidence-based medicine and can only be selected for individualized treatment. Chemotherapy-induced thrombocytopenia mainly uses platelet transfusion and the administration of platelet-promoting growth factors, such as interleukin-11, TPO and TPO receptor agonists Romiplostim and Eltrombopag.
[0004] Traditional Chinese medicine has unique advantages in treating thrombocytopenia, as it can treat both the symptoms and the root cause. Many Chinese medicines can increase the number of peripheral platelets in patients through multiple targets, and have definite clinical treatment effects. However, their ingredients are complex and the effective components are unclear, which limits their further development and clinical application.
[0005] The plant Sarcandra strychnifolia of the family Chrysanthemiaceae has the effects of promoting blood circulation and removing blood stasis, cooling blood and stopping bleeding, and can be used to treat thrombocytopenia. Two monomer compounds were screened out from Sarcandra strychnifolia and blood migration components: Daucosterol (molecular formula: C 35 H 60 O6, CAS No.: 474-58-8, molecular structure see Figure 1 ) and rosmarinic acid 4-O-β-D-glucoside (Molecular formula: C 24 H 26 O13 , CAS No.: 910028-78-3, molecular structure see Figure 2 ), studies have reported that the pharmacological effects of carotene are mainly in anti-tumor, anti-oxidation, neuroprotection, and treatment of diabetes (Current Status of Research on Pharmacological Effects of Carotene, Chinese Journal of Clinical Pharmacology, 2019, 35(07): 722-724), and there is a patent for the preparation or prevention and treatment of heart failure (Application of carotene in the Preparation of Drugs for the Prevention or Treatment of Heart Failure, 2023-05-02). There is a patent for the application of rosmarinic acid-4-O-β-D-glucose in the preparation of pre-treatment drugs for influenza (Application of rosmarinic acid-4-O-Β-D-glucoside in the Preparation of Pre-treatment Drugs for Influenza, 2018-05-01). However, there is currently no application of carotene and rosmarinic acid-4-O-β-D-glucose alone or in combination to promote the differentiation, maturation and production of platelets from megakaryocytes. Summary of the invention
[0006] The purpose of the present invention is to solve the above problems and provide the use of carotene and rosmarinic acid-4-O-β-D-glucose in the preparation of a drug for treating thrombocytopenia. Carotene and rosmarinic acid-4-O-β-D-glucose can generate platelets by promoting the differentiation and maturation of megakaryocytes.
[0007] The present invention is further configured as follows: the medicine is prepared from a composition of carotene and rosmarinic acid-4-O-β-D-glucose monomers and conventional auxiliary materials in pharmaceutical preparations.
[0008] The present invention is further configured as follows: the drug dosage forms include tablets, capsules and injections.
[0009] In summary, the present invention has the following beneficial effects:
[0010] The experimental results of the present invention show that carotene and rosmarinic acid-4-O-β-D-glucose significantly promote the differentiation and maturation of megakaryocytes and the generation of platelets. The present invention can provide a new therapeutic drug for treating thrombocytopenia. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1 is the molecular structural formula of carotene (Dau) in the present invention;
[0012] Figure 2 is the molecular structural formula of rosmarinic acid-4-O-β-D-glucose (Ros) in the present invention;
[0013] Figure 3 The effect of carotene (Dau) and rosmarinic acid-4-O-β-D-glucose (Ros) in Example 1 of the present invention on the level of megakaryocyte surface molecule CD41a in an in vitro megakaryocyte differentiation and maturation disorder model;
[0014] Figure 4 The effect of carotene (Dau) and rosmarinic acid-4-O-β-D-glucose (Ros) in Example 1 of the present invention on the level of megakaryocyte surface molecule CD61 in an in vitro megakaryocyte differentiation and maturation disorder model;
[0015] Figure 5 The effect of carotene (Dau) in Example 1 of the present invention on the polyploidization of megakaryocytes in the in vitro megakaryocyte differentiation and maturation disorder model;
[0016] Figure 6 The effect of rosmarinic acid-4-O-β-D-glucose (Ros) in Example 1 of the present invention on the polyploidization of megakaryocytes in an in vitro megakaryocyte differentiation and maturation disorder model;
[0017] Figure 7 The effect of carotene (Dau) and rosmarinic acid-4-O-β-D-glucose (Ros) on the platelet count of SD rats with immune thrombocytopenia in Example 2 of the present invention;
[0018] Figure 8 This is the effect of radix glucosinolate (Dau) and rosmarinic acid-4-O-β-D-glucose (Ros) on the number of polyploid megakaryocytes in immune thrombocytopenia SD rats in Example 2 of the present invention. DETAILED DESCRIPTION
[0019] In order to enable those skilled in the art to better understand the solution of the present invention, the technical solution of the present invention will be further described in detail below in conjunction with the embodiments of the present invention and the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.
[0020] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present invention can be combined with each other. The present invention will be described in detail below in conjunction with the embodiments.
[0021] The invention discloses an application of carotene and rosmarinic acid-4-O-β-D-glucose in the preparation of a drug for treating thrombocytopenia. The drug is prepared from a monomer composition of carotene and rosmarinic acid-4-O-β-D-glucose and pharmaceutically acceptable excipients. The excipients can be conventional excipients commonly used in pharmaceutical preparations. The drug is in the form of solid, liquid or semisolid dosage forms, including tablets, injections and capsules.
[0022] The experimental results show that carotene and rosmarinic acid-4-O-β-D-glucose significantly promote the differentiation and maturation of megakaryocytes and the production of platelets. The specific examples are as follows:
[0023] Embodiment 1:
[0024] Carotene and rosmarinic acid-4-O-β-D-glucose significantly promoted the differentiation and maturation of megakaryocytes in vitro.
[0025] 1. Experimental Materials
[0026] Human megakaryocytic leukemia cells Dami were purchased from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, cryopreserved at Jiangxi University of Traditional Chinese Medicine, and used after thawing according to conventional methods.
[0027] Drugs and reagents: Phorbol 12-myristate 13-acetate (PMA, catalog number: SLCL5743), Sigma-Aldrich, USA; rabbit anti-rat platelet serum (APS) and total flavonoids of Sarcandra sylvestris were prepared in the laboratory; rosmarinic acid-4-O-β-D-glucose (batch number: wkq22082607) and carotene (catalog number: wkq22082503) were purchased from Sichuan Weikeqi Biotechnology Co., Ltd.; RPMI Medium 1640 culture medium (catalog number: 8121738), Gibco, USA; fetal bovine serum (catalog number: 22010701), Zhejiang Tianhang Biotechnology Co., Ltd.; Anti-Human CD41a PE (catalog number: 12-0419-42), Anti-Human CD61 FITC (Cat. No. 11-0619-42), antibodies were purchased from eBioscience, USA; dimethyl sulfoxide (DMSO, Cat. No. 1209MO34), Beijing Solebao Biotechnology Co., Ltd. Rabbit anti-rat platelet serum (APS) (Cat. No. 201108), according to the method of Lu Xiaonan et al. [Lu Xiaonan, Peng Wenhu, Xu Guoliang, et al. Effect of total flavonoids of Sarcandra sylvestris on the microenvironment of bone marrow cells in rats with immune thrombocytopenia [J]. Chinese Pharmacology and Clinical Medicine. 2015, 31(06): 66-69.] was customized by Beijing Dingguo Changsheng Biotechnology Co., Ltd. Double antibody and DMSO are conventional cell culture reagents
[0028] 2. Experimental methods
[0029] 2.1 Cell culture
[0030] Human megakaryocytic leukemia cells Dami were cultured in RPMI-1640 medium containing 10% FBS and double antibodies (penicillin 100 U / mL, streptomycin 0.1 mg / mL) at 37°C, 5% CO2, and saturated humidity, and the medium was changed every 2 to 3 days.
[0031] 2.2 Solution preparation
[0032] Carotene and rosmarinic acid-4-O-β-D-glucose stock solution: Dissolve carotene and rosmarinic acid-4-O-β-D-glucose in DMSO to 1 mg mL -1 The drug stock solution was stored in a 4°C refrigerator for later use. During the experiment, one thousandth of the drug stock solution was mixed with ultrapure water to a final concentration of 1 μg mL -1 of solvent.
[0033] 2.3 Experimental Grouping
[0034] PMA and APS were used to construct an in vitro megakaryocyte differentiation and maturation disorder model to study the effect of drugs on the improvement of megakaryocyte differentiation and maturation in this model. Dami cells in a good logarithmic growth phase were used for the experiment. -1 PMA with a volume fraction of 1% and APS with a volume fraction of 1% were used together to act on Dami cells to construct an in vitro megakaryocyte differentiation and maturation disorder model. The experiment was divided into a blank control group (Control group), a PMA-induced group (5 ng·mL -1 ), APS model group (5 ng·mL -1 PMA+1% APS, Model group) and high, medium and low dose groups of carotene and rosmarinic acid-4-O-β-D-glucose (40, 60, 80 μg mL -1 Chinese medicine monomer + 5ng·mL -1 PMA+1% APS), and after cell inoculation, the culture plate was moved into a 37°C, 5% CO2 incubator.
[0035] 2.4 Flow cytometry to determine the effect of drugs on megakaryocyte differentiation of human megakaryocytic leukemia cells Dami
[0036] Cells in logarithmic growth phase were taken and inoculated into 12-well plates at 6×104 cells per well (volume 1 mL). The groups were the same as in item "2.3", with 3 replicates per group. After 48 hours of drug intervention, cells from each group were collected into 2 mL centrifuge tubes, washed twice by centrifugation with phosphate buffered saline (PBS), and resuspended with 500 μL PBS; 5 μL Anti-Human CD41a PE, Anti Human CD42bFITC, and Anti-Human CD61 FITC dyes were added, mixed, and stained at room temperature in the dark for 30 minutes. After filtering with a cell mesh, the expression of surface marker molecules CD41a and CD61 of megakaryocyte differentiation and maturation was detected by flow cytometry.
[0037] 2.5 Flow cytometry to determine the effect of drugs on megakaryocyte differentiation and maturation (polyploidization) of human megakaryocytic leukemia cells Dami
[0038] The samples were grouped as in 2.4. After 72 hours in a 37°C, 5% CO2 incubator, Dami cells were collected into 2 mL centrifuge tubes and washed twice with PBS by centrifugation. The cells were resuspended in 500 μL PBS, and 1 mL DNA Staining Solution and 10 μL PI staining solution were added to each group. After mixing, staining was carried out at room temperature in the dark for 30 minutes. Excess staining solution was removed by centrifugation, and after resuspension, the cells were filtered using a 200-mesh cell sieve. The expression of megakaryocyte polyploidy was detected by flow cytometry.
[0039] GraphPad Prism 8.0 software was used for data analysis. The experimental results were expressed as mean ± standard deviation. One-way analysis of variance was used to compare data between different groups. P < 0.05 indicated that the difference between the groups was statistically significant.
[0040] 3. Results Analysis
[0041] 3.1 Effects of drugs on megakaryocyte differentiation of human megakaryocytic leukemia cell line Dami
[0042] like Figure 3 , Figure 4 As shown in the results, after the megakaryocyte differentiation and maturation disorder model was intervened by rosmarinic acid-4-O-β-D-glucose, the expression levels of CD41a and CD61 on the surface of Dami cells in the low, medium and high dose groups of rosmarinic acid-4-O-β-D-glucose were significantly increased compared with the Model group, and the difference was statistically significant (P < 0.01). After the megakaryocyte differentiation and maturation disorder model was intervened by carotenoids, the expression levels of CD41a and CD61 on the surface of Dami cells in the low, medium and high dose groups of carotenoids were significantly increased compared with the Model group, and the differences were statistically significant (P < 0.05, P < 0.01). The results showed that both active ingredients can effectively promote megakaryocyte differentiation.
[0043] 3.2 Effects of drugs on polyploidization of human megakaryocyte Dami
[0044] like Figure 5 , Figure 6As shown in the figure, after the intervention of rosmarinic acid-4-O-β-D-glucose and carotenoids, the expression levels of carotenoids in the low, medium and high concentration groups in 2N were significantly decreased compared with the Model group (P<0.01); in 4N, the expression levels were significantly increased compared with the Model group (P<0.01); in >8N, the expression levels were decreased compared with the Model group (P<0.05). However, the expression levels of rosmarinic acid-4-O-β-D-glucose in the low, medium and high concentration groups in 2N were significantly decreased compared with the Model group (P<0.01); in 4N, the expression levels were significantly increased compared with the Model group (P<0.01); in >8N, the expression levels of the other two groups were significantly increased compared with the Model group except for the high-dose group (P<0.01). The results showed that rosmarinic acid-4-O-β-D-glucose and carotenoids can effectively promote the polyploidization of megakaryocytes.
[0045] The above research results show that carotene (Dau) and rosmarinic acid-4-O-β-D-glucose (Ros) can significantly promote the differentiation, maturation and polyploidy of human megakaryocytes Dami.
[0046] Example 2
[0047] Carotene and rosmarinic acid-4-O-β-D-glucose significantly promoted the differentiation and maturation of megakaryocytes in the SD rat model of immune thrombocytopenia (ITP) and increased the number of platelets.
[0048] 1. Experimental Materials
[0049] The animals used in this experiment were 60 SPF-grade healthy male SD rats, weighing 140-160 g, purchased from Hunan Slake Jingda Experimental Animal Co., Ltd., license number: SCXK (Xiang) 2019-0004, and maintained in a SPF-grade environment in a standardized animal center with free access to food. All procedures in this animal experiment were performed in accordance with the Guide for the Care and Use of Animals of the Animal Care Committee and the National Institutes of Health.
[0050] Rabbit anti-rat platelet serum (APS) (Cat. No.: 201108) was customized by Beijing Dingguo Changsheng Biotechnology Co., Ltd. according to the method of Lu Xiaonan et al. [Lu Xiaonan, Peng Wenhu, Xu Guoliang, et al. Effects of total flavonoids of Sarcandra sylvestris on the microenvironment of bone marrow cells in rats with immune thrombocytopenia [J]. Chinese Pharmacology and Clinical Medicine. 2015, 31(06): 66-69.].
[0051] 2. Experimental methods
[0052] Sixty SD rats were fed adaptively for 1 week. After blood was collected from their orbits to measure their platelet count, the rats were randomly divided into a normal group (Control), an ITP model group (ITPModel), a high-dose group (20, 40 mg kg-1) of carotene and rosmarinic acid-4-O-β-D-glucose, and a low-dose group (20, 40 mg kg-1) of carotene and rosmarinic acid-4-O-β-D-glucose. -1 ) groups, 10 rats in each group. Except for the normal group, which was injected with normal saline, the other rats were intraperitoneally injected with 1:4 diluted APS at a volume of 1 ml / 200 g on days 1, 3, 4, 6, 7, and 8 to establish immune thrombocytopenia rat models. The APS injection and drug administration groups were intragastrically administered with high and low doses (20 and 40 mg kg-1 of carotene and rosmarinic acid-4-O-β-D-glucose) of -1 ) group, control group and model group were gavaged with an equal amount of normal saline. Blood was collected from the orbits on days 0, 3, 6 and 9 during the modeling period to measure the platelet count. After the experiment, the animal weight and peripheral platelet count were measured. The animals were dissected, the femurs were separated, and the femurs on both sides were removed under sterile conditions and peeled clean. One of the femurs was fixed with 4% paraformaldehyde, embedded in paraffin after decalcification, and sliced. Hematoxylin-eosin (HE) staining was performed, and the number and differentiation of bone marrow megakaryocytes in different groups were observed, counted and analyzed under a microscope.
[0053] Statistical analysis: GraphPad Prism 8.0 software was used for data analysis. The experimental results were expressed as mean ± standard deviation. One-way analysis of variance was used to compare data between different groups. P < 0.05 indicated that the difference between the groups was statistically significant.
[0054] 3. Results Analysis
[0055] After APS injection modeling, platelet changes such as Figure 7 As shown in the figure, there was no significant difference among the groups on the third day of modeling; the model group was lower than the normal group from the sixth day after modeling, and it was statistically significant (P<0.01). Compared with the model group, after drug intervention, high and low doses (20 and 40 mg kg -1 ) groups all had significant effects. On the 6th and 9th days, the number of peripheral platelets in rats in each medication group increased significantly, and it was statistically significant (P<0.01). After HE staining, it was found that some megakaryocytes could be observed to have multiple nuclei, that is, polyploid megakaryocytes, and polyploidization is a typical event of megakaryocyte differentiation and maturation. Statistical results Figure 8 The results showed that the high and low doses (20 and 40 mg kg -1) group can increase the number of differentiated mature megakaryocytes (P<0.01). This shows that carotene and rosmarinic acid-4-O-β-D-glucose can improve the number of mature megakaryocytes in ITP animal models and increase the number of peripheral platelets. This suggests that carotene and rosmarinic acid-4-O-β-D-glucose are expected to improve clinical megakaryocyte differentiation and maturation disorder-related diseases and increase the number of platelets in patients.
[0056] This specific embodiment is merely an explanation of the present invention and is not a limitation of the present invention. After reading this specification, those skilled in the art may make non-creative modifications to the present embodiment as needed. However, as long as they are within the scope of the claims of the present invention, they are protected by the patent law.
Claims
1. Application of carotene and rosmarinic acid-4-O-β-D-glucose in the preparation of drugs for treating thrombocytopenia.
2. Use of the carotene and rosmarinic acid-4-O-β-D-glucose according to claim 1 in the preparation of a drug for treating thrombocytopenia, Features: The medicine is prepared from a composition of carotene and rosmarinic acid-4-O-β-D-glucose monomers and conventional auxiliary materials in medicine preparations.
3. Use of the carotene and rosmarinic acid-4-O-β-D-glucose according to claim 2 in the preparation of a drug for treating thrombocytopenia, Features: The pharmaceutical dosage forms include tablets, capsules and injections.
